This page is not the official website. Generated by AI, does not constitute any advice. If needed, please click here to visit the corresponding official website.

Cancer Precision Medicine – Putting the Patient First

NanoMab is a privately held biopharmaceutical company focused on developing next-generation radiopharmaceuticals for targeted cancer therapy and diagnosis.

Learn More About Our Technology
NanoMab Technology

Our Mission

NanoMab is developing medicine for fast and specific delivery of radiation to treat cancer. A therapeutic product is made by a camelid antibody labeled with a radioisotope of therapeutic radiation.

This therapeutic product is paired with a diagnostic, using the same antibody vector but labeled with a lower radiation radioisotope for imaging. Our goal is to develop a pipeline of theranostic couple camelid antibodies with our proprietary camelid antibodies platform.

Highly Stable

Temperature and pH resistant

New Binding Domain

Smaller size for more binding options

Customized Manipulation

Multivalent and radiolabeling

Easy Manufacturing

Low cost production (Pichia / E.coli)

About NanoMab

A biopharmaceutical company at the forefront of cancer precision medicine.

Our Mission

We are developing medicine for fast and specific delivery of radiation to treat cancer.

Our Vision

To address the unmet medical need for cancer patients across the world.

Our Values

Putting the patient first in everything we do.

Next-Generation Radiopharmaceuticals

Our proprietary camelid antibody platform enables the development of highly specific theranostic agents for cancer.

Camelid Antibodies

Small, stable single-domain antibodies derived from camelids offer superior tissue penetration and rapid clearance.

Theranostic Pairs

Matched diagnostic and therapeutic agents using the same targeting vector for precision treatment.

Radiolabeling Flexibility

Compatible with a range of radioisotopes for imaging (e.g., ⁶⁸Ga, ⁹⁹ᵐTc) and therapy (e.g., ¹⁷⁷Lu, ²²⁵Ac).

Multivalent Constructs

Engineered to carry multiple payloads for enhanced efficacy and targeting.

Scalable Production

Manufactured in microbial systems (Pichia/E.coli) enabling low-cost, high-yield production.

pH & Temperature Resilience

Stable under a wide range of conditions, improving shelf life and in vivo performance.

Product Pipeline

Our pipeline focuses on developing targeted radiopharmaceuticals for various cancers using our proprietary camelid antibody platform.

NM-PSMA-1

PSMA-targeting theranostic for prostate cancer.

  • Target: PSMA
  • Type: Theranostic
  • Stage: Preclinical

NM-SSTR-1

Somatostatin receptor-targeting agent for neuroendocrine tumors.

  • Target: SSTR2
  • Type: Diagnostic/Therapeutic
  • Stage: Lead Optimization

NM-EGFR-1

EGFR-targeting radiopharmaceutical for glioblastoma and NSCLC.

  • Target: EGFR
  • Type: Therapeutic
  • Stage: Discovery

NM-FAP-1

Fibroblast Activation Protein (FAP) inhibitor for solid tumors.

  • Target: FAP
  • Type: Theranostic
  • Stage: Preclinical

NM-HER2-1

HER2-targeting agent for breast and gastric cancers.

  • Target: HER2
  • Type: Diagnostic
  • Stage: Lead Optimization

NM-BONE-1

Bone-seeking radiopharmaceutical for metastatic bone lesions.

  • Target: Bone Matrix
  • Type: Therapeutic
  • Stage: Discovery

NM-CEA-1

Carcinoembryonic antigen (CEA) targeting for colorectal cancer.

  • Target: CEA
  • Type: Diagnostic
  • Stage: Preclinical

NM-PDL1-1

PD-L1 imaging agent to assess immunotherapy eligibility.

  • Target: PD-L1
  • Type: Diagnostic
  • Stage: Discovery

8+

Pipeline Candidates

4

Theranostic Pairs

3

Cancer Types Targeted

2

Global Sites

Trusted Collaborators

We partner with leading institutions and companies to advance cancer therapeutics.

NHS Shanghai General Hospital Lantheus

Frequently Asked Questions

What are radiopharmaceuticals?

Radiopharmaceuticals are drugs that contain radioactive isotopes used for diagnosis or therapy in nuclear medicine.

What is a theranostic?

A theranostic is a pair of diagnostic and therapeutic agents that use the same targeting molecule, enabling personalized treatment.

Why camelid antibodies?

Camelid antibodies (nanobodies) are smaller, more stable, and penetrate tissues more effectively than conventional antibodies.

Where is NanoMab headquartered?

NanoMab has operations in Shanghai, China and Borehamwood, United Kingdom.

Is NanoMab publicly traded?

No, NanoMab is a privately held biopharmaceutical company.

Get in Touch

For partnership, collaboration, or general inquiries, visit the official NanoMab website.

+86 021 6229 9192

info@nano-mab.com

Shanghai, China & Borehamwood, UK

Visit Official Website
China Quality Suppliers fobcompany.info

Notice for Buyers: If you are a buyer, the above information is generated by AI collection and does not constitute any advice. If necessary, please visit the corresponding official website.

For Domain Owners: If you are the domain owner and do not want to be included by fobcompany.info, please contact support@fobcompany.info via your corporate email to cancel. We will cancel your inclusion within 3 business days.

如果您是域名所有者 不想被fobcompany.info收录 请用企业邮箱联系support@fobcompany.info 取消收录 我们将在3个工作日取消您的收录

Service Request: If you are other domain and want to be included, please contact support@fobcompany.info

如果您是其他域名合作 也请联系support@fobcompany.info